Médecine

Paramédical

Autres domaines


S'abonner

Covid-19 severe hypoxemic pneumonia: A clinical experience using high-flow nasal oxygen therapy as first-line management - 06/12/21

Doi : 10.1016/j.resmer.2021.100834 
G. Beduneau a, , D. Boyer b, P.-G. Guitard c, P. Gouin c, D. Carpentier b, S. Grangé b, B. Veber c, C. Girault a, F. Tamion d
a UNIROUEN, EA 3830, medical intensive care unit, Rouen university hospital, Normandie university, 76000 Rouen, France 
b Medical intensive care unit, Rouen university hospital, 76000 Rouen, France 
c Department of anesthesiology and critical care, Rouen university hospital, 76000 Rouen, France 
d UNIROUEN, Inserm U1096, medical intensive care unit, Rouen university hospital, Normandie university, 76000 Rouen, France 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Purpose

To report a French experience in patients admitted to Intensive Care Unit (ICU) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requiring high fractional concentration of inspired oxygen supported by high flow nasal cannula (HFNC) as first-line therapy.

Methods

Retrospective cohort study conducted in two ICUs of a French university hospital. All consecutive patients admitted during 28-days after the first admission for SARS-CoV-2 pneumonia were screened. Demographic, clinical, respiratory support, specific therapeutics, ICU length-of-stay and survival data were collected.

Results

Data of 43 patients were analyzed: mainly men (72%), median age 61 (51–69) years, median body mass index of 28 (25–31) kg/m2, median simplified acute physiology score (SAPS II) of 29 (22–37) and median PaO2/fraction of inspired oxygen (FiO2) (P/F) ratio of 146 (100–189) mmHg. HFNC was initiated at ICU admission in 76% of patients. Median flow was 50 (45–50) L/min and median FiO2 was 0.6 (0.5–0.8). 79% of patients presented at least one comorbidity, mainly hypertension (58%). At day (D) 28, 32% of patients required invasive mechanical ventilation, 3 patients died in ICU. Risk factors for intubation were diabetes (10% vs. 43%, P=0.04) and extensive lesions on chest computed tomography (CT) (P=0.023). Patients with more than 25% of lesions on chest CT were more frequently intubated during ICU stay (P=0.012). At ICU admission (D1), patients with higher SAPS II and Sequential Organ Failure Assessment (SOFA) scores (respectively 39 (28–50) vs. 27 (22–31), P=0.0031 and 5 (2–8) vs. 2 (2–2.2), P=0.0019), and a lower P/F ratio (98 (63–109) vs. 178 (126–206), P=0.0005) were more frequently intubated. Among non-intubated patients, the median lowest P/F was 131 (85–180) mmHg. Four caregivers had to stop working following coronavirus 2 contamination, but did not require hospitalization.

Conclusion

Our clinical experience supports the use of HFNC as first line-therapy in patients with SARS-COV-2 pneumonia for whom face mask oxygen does not provide adequate respiratory support.

Le texte complet de cet article est disponible en PDF.

Keywords : SARS-COV-2 pneumonia, Hypoxemia, High flow oxygen therapy, Mechanical ventilation, Outcomes

Abbreviations : ARF, SARS-CoV-2, COVID-19, ICU, FiO2, HFNC, RT-PCR, BMI, SAPSII, SOFA, ARDS, P/F ratio


Plan


© 2021  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 80

Article 100834- novembre 2021 Retour au numéro
Article précédent Article précédent
  • The 3 Minute Step Test is a validated field test to evaluate the functional exercise capacity in children aged 6 to 12
  • A. Iturain Barrón, S. Quintana Riera, G. Reychler
| Article suivant Article suivant
  • Prognostic utility of various multidimensional grading scales among Saudi patients with bronchiectasis
  • Abdullah AL-Harbi, Majed AL-Ghamdi, Abdelmonim Abdulrahman, Mohammad Khan, Sulaiman AL-Rajhi, Hamdan AL-Jahdali

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.